Home - Lustgarten Foundation: Pancreatic Cancer Research
LustGarden Foundation for Pancreatic Cancer Research

Pancreatic Cancer Research

As the largest private funder of pancreatic cancer research, we are relentlessly focused on improving patient outcomes and we are making progress every day. Thanks to separate funding to support administrative expenses, 100 percent of every donation goes directly to research.

Navigating Pancreatic Cancer

We are here to empower you to ask bold questions, seek out the best treatment options, and face the unique challenges of pancreatic cancer head-on. We want to give you the resources and information you need to make informed decisions that are best for you.

Patient Checklist

Checklist

August 1, 2018 ladmin
As overwhelming as a pancreatic cancer diagnosis is, it is important to act quickly and put a treatment plan into place. Treatment should ideally begin within one month after you receive your diagnosis. Understand your disease. Thoroughly understand what stage of pancreatic cancer you have and inquire about having your blood and tumor genetically sequenced. […]
Lets Win! Pancreatic Cancer

Let’s Win! Pancreatic Cancer

July 20, 2018 ladmin
LET’S WIN! Pancreatic Cancer A Dynamic Way to Share Information Recognizing that there is an urgent need for patients to communicate amongst themselves and with the medical community about potentially life-changing treatments and clinical trials, we are proud to be affiliated with Let’s Win. Let’s Win is an interactive online community where patients and families […]

Pancreatic Cancer Connections

July 7, 2018 ladmin
Pancreatic Cancer Connections is online social community that provides a safe space for pancreatic cancer patients and their loved ones to share their experiences, get valuable coping resources, and support one another. Patients interact with others who are facing a pancreatic cancer and can post questions to the board or message other members privately. This community forum is a valuable resource for patients, caregivers, and their loved ones to refer to at various stages of their treatment and recovery. Patients and loved ones can sign up for Pancreatic Cancer Connections at no cost and will be welcomed into an engaging and supportive community to discuss topics including treatment options, nutrition, and coping with the disease. Pancreatic Cancer Connections is hosted by Inspire, a leading healthcare social network that connects more than 1,000,000 patients and caregivers.

Lustgarten News

View All Articles

In Person Walks
Are Back!

Join Hundreds of Walkers and Runners Across New York on June 27th  in the Critical Fight Against Pancreatic Cancer. The Lustgarten Foundation’s New York Walk Series is your chance to join forces with hundreds of others whose lives have been touched by pancreatic cancer. Together we will raise the critical funds and awareness needed to defeat this this devastating disease. Register. Donate. Fundraise. Walk where you want, when you want in your neighborhood. 100% of all donations fund lifesaving pancreatic cancer research. Whether you walk with us in New York City or walk in your own neighborhood, your action will change lives and inspire others! Choose an event near you and join our community of patients, survivors and loved ones coming together to celebrate, reflect and remember as we move closer to a cure for pancreatic cancer. Your Walk for Research will leave you energized and optimistic about the future. Together, we will defeat this disease!

Learn More

Lustgarten
Loot

The wait is over to get your LUSTGARTEN LOOT! Our first-ever online store is now LIVE. Shop all of our great Lustgarten merchandise, from tumblers to T-shirts to a cozy and versatile 4-in-1 blanket. We have something for everyone—even your four-legged friends! All proceeds fund pancreatic cancer research, so start shopping today!

Learn More

Register For Lustgarten Live!

Welcome to LustgartenLIVE! a new quarterly series of webinars designed to bring you face-to-face with the best researchers investigating pancreatic cancer. Moderated by Andrew Rakeman, PhD , Vice President of Research, each webinar in the series will focus on a different aspect of the research funded through your donations. REGISTRATION IS NOW OPEN for From the Lab to You: Clinical Advances
Clinical trials are designed to find more effective treatments than those currently available and provide a unique opportunity to better understand human disease. Clinical trials are especially important for pancreatic cancer patients, given the limited treatment options currently available. However, currently fewer than 5% of pancreatic cancer patients are enrolled in clinical trials. The Lustgarten Foundation is working to improve clinical trial participation by moving promising therapies into trials as quickly as possible, with the goal of having trials available for patients at every stage of the disease. During this webinar, two world-renowned pancreatic cancer researchers and clinicians, Dr. Elizabeth Jaffee of Johns Hopkins and Dr. Brian Wolpin of the Dana-Farber Cancer Institute, explain the Foundation’s critical role in moving research from the lab to the clinic, advancing clinical trials and better therapies. The Foundation established the Clinical Accelerator Initiative (CAI) to shorten the time from clinical trial concept to launch using a Lustgarten-developed process based on the best available science. These “smarter” clinical trials will examine cutting-edge biomarkers to observe key indicators of how the treatment is working and will generate large volumes of data scientists can use now and in the future.

Learn More

Pancreatic Cancer News

View All Articles

Study identifies biomarker that could help to diagnose pancreatic cancer

29. 6. 21 ladmin
Researchers from Queen Mary University of London have identified a protein that could be used to aid in the diagnosis of pancreatic cancer. Findings from the new study suggest that a protein called pentraxin 3 (PTX3) may be a specific diagnostic biomarker – or biological measure – for pancreatic cancer, with the ability to differentiate […]

Blood test can accurately detect 50 types of early-stage cancer

28. 6. 21 ladmin
A simple blood test that can detect more than 50 types of cancer before any clinical signs or symptoms of the disease is accurate enough to be rolled out as a multi-cancer screening test, according to scientists. The test, which is also being piloted by NHS England, is aimed at people at higher risk of the […]

How pancreatic cancer cells dodge drug treatments

22. 6. 21 ladmin
Cancer cells can become resistant to treatments through adaptation, making them notoriously tricky to defeat and highly lethal. Cold Spring Harbor Laboratory (CSHL) Cancer Center Director David Tuveson and his team investigated the basis of “adaptive resistance” common to pancreatic cancer. They discovered one of the backups to which these cells switch when confronted with […]

Novel drug class shows potential to treat cancer patients with faulty BRCA genes

17. 6. 21 ladmin
Scientists have identified a new class of targeted cancer drugs that offer the potential to treat patients whose tumors have faulty copies of the BRCA cancer genes. The drugs, known as POLQ inhibitors, specifically kill cancer cells with mutations in the BRCA genes while leaving healthy cells unharmed. And crucially, they can kill cancer cells […]

‘Bad fat’ suppresses killer T cells from attacking cancer

10. 6. 21 ladmin
LA JOLLA–(June 10, 2021) In order for cancer to grow and spread, it has to evade detection by our immune cells, particularly specialized “killer” T cells. Salk researchers led by Professor Susan Kaech have found that the environment inside tumors (the tumor microenvironment) contains an abundance of oxidized fat molecules, which, when ingested by the […]

Oncogenic KRAS engages an RSK1/NF1 pathway to inhibit wild-type RAS signaling in pancreatic cancer

24. 5. 21 ladmin
For decades, KRAS interactors have been sought after as potential therapeutic targets in KRAS mutant cancers, especially pancreatic ductal adenocarcinoma (PDAC). Our proximity labeling screen with KRAS in PDAC cells highlights RSK1 as a notable mutant-specific interactor. Functionally, we show that RSK1 mediates negative feedback on wild-type (WT) KRAS in PDAC cells. Targeting oncogenic KRAS […]

Predicting chemotherapy response and tailoring treatments for pancreatic cancer patients

24. 5. 21 ladmin
By 2030, pancreatic ductal adenocarcinoma (PDAC), the most lethal form of pancreatic cancer, is projected to become the second leading cause of cancer-related deaths in the United States. Not only are therapeutic options limited, but nearly half of all PDAC patients who have their tumors removed surgically experience disease recurrence within a year, despite receiving […]

Join Us

Get Involved Today

Get inspired and connect with patients, survivors and loved ones who are all on the same journey.

Back to Top